Rob Healy

Provides wealth management, securities trading and sales, corporate finance and investment banking services

Develops, manufactures, distributes and retails educational products and teaching solutions

Provides consulting and managed network services

Provides marketing and technology solutions to the real estate industry

Provides trading solutions

William Blair Capital Partners (WBCP) focuses on private placements, PIPES and the investment of funds provided by partners of the firm. They invest in the following sectors: business services, financial services, consumer, healthcare services, healthcare products and technology. Within the business and financial services sectors, WBCP focuses on accounts receivable management, asset management services, data analytics, distribution services, education/educational services, interactive media, niche consulting, payment processing, payroll processing, research products/services, specialty insurance products and specialized marketing services. WBCP seeks investments in outstanding growth companies in the consumer sector. The firm looks for companies that need capital to expand through organic growth, regional expansion or through acquisition of other market players. They focus primarily on two niches within the consumer segment: (1) companies involved in the sale of new and novel products and services to the consumer and companies involved in the sale of well-established products in new and novel ways. WBCP seeks to invest in growing, well-managed companies with strong management teams that are, or have the potential to become, leaders in their market niche. Within the healthcare sector, WBCP invests primarily in the medical devices, biopharmaceuticals and healthcare services industries. The firm looks for innovative companies with products that address unmet medical needs. They are particularly interested in therapeutic areas in which relatively little capital has been historically deployed, including gastroenterology, neurology/neurosurgery and cosmetic surgery and aesthetics. They may also consider investment opportunities in the orthopedic, spine and cardiovascular segments. In the biopharmaceutical industry, WBCP invests primarily in companies that have late-stage (phase II clinical trials or later) compounds or that have approved products. The firm also pursues opportunities to start and nurture pharmaceutical companies in the dermatology, neurology, rheumatology and gastroenterology specialties. WBCP also invests in small market companies with annual revenues of $50 million to $300 million that have not generated strong commercial or development interest from large pharmaceutical companies. WBCP considers investments in healthcare companies that provide services to patients in the outpatient or short-stay settings and in companies that provide outsourced business services to larger healthcare providers such as hospitals or surgery centers. The firm is particularly interested in service companies that pursue segments of the healthcare economy in which the patient pays directly for the service or that provide business-to-business services to healthcare providers. They also invest in companies that provide medical services to governmental healthcare programs such as Medicare and Medicaid. WBCP invests technology companies primarily in the following areas: wireless semiconductors, consumer electronic semiconductors/software, wireless Internet and software as service (SaaS). They firm seeks to invest in companies with (1) platform technology including core technology can be applied to multiple markets across multiple product lines (2) scaleable and capital efficient business models (3) market opportunities that have been validated by customers (4) disruptive technology that is non-disruptive to implement (5) a defensible and sustainable technology lead (6) multiple exit opportunities including acquisition and IPO and (7) compelling growth rates appropriate for their business model. WMCP invests in companies that require funds for product development, sales, marketing and operations. They do not invest in technology development.

Designs and develops thermal printing solutions

Functions as a College/University

ClearLight Partners invest in middle market companies located in the United States and Canada with an EBITDA of $4 - 15 million and revenues of $25 - 250 million. The firm focuses on companies across a broad range of sectors and industries. It provides equity and mezzanine financing for buyout transactions with an investment size of $10 - 50 million and also makes co-investments. It acts as a lead investor and it takes a seat on the board of directors.